Efficacy and Safety of Lenvatinib Versus Atezolizumab plus Bevacizumab as First-Line Systemic Therapies for Hepatocellular Carcinoma : Experience from a Single UK Centre
SCIREA Journal of Clinical Medicine · 29.05.2026
DOI: 10.54647/cm321476 ↗Kurz gefasst
Fachartikel in der Zeitschrift SCIREA Journal of Clinical Medicine, online erschienen am 29.05.2026. Verfasst von Eric Ka Chai LEE und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
LEE, E. K. C., LOO, S. W., & COLLINS, J. L. (2026). Efficacy and Safety of Lenvatinib Versus Atezolizumab plus Bevacizumab as First-Line Systemic Therapies for Hepatocellular Carcinoma : Experience from a Single UK Centre. SCIREA Journal of Clinical Medicine. https://doi.org/10.54647/cm321476
Vancouver
LEE EKC, LOO SW, COLLINS JL. Efficacy and Safety of Lenvatinib Versus Atezolizumab plus Bevacizumab as First-Line Systemic Therapies for Hepatocellular Carcinoma : Experience from a Single UK Centre. SCIREA Journal of Clinical Medicine. 2026. doi:10.54647/cm321476
BibTeX
@article{LEE2026,
author = {LEE, Eric Ka Chai and LOO, Suat Wei and COLLINS, Jennifer Louise},
title = {Efficacy and Safety of Lenvatinib Versus Atezolizumab plus Bevacizumab as First-Line Systemic Therapies for Hepatocellular Carcinoma : Experience from a Single UK Centre},
journal = {SCIREA Journal of Clinical Medicine},
year = {2026},
doi = {10.54647/cm321476}
}
EUVIMED